
THE MITOCHONDRIAL tRNAGly T10003C MUTATION
MAY NOT BE ASSOCIATED WITH DIABETES MELLITUS Yuan Q, Zhao ZG, Yuan HJ *Corresponding Author: Dr. Qian Yuan, Department of Endocrinology and Metabolism, People’s Hospital of Zhengzhou
University, Weiwu Road 7, Zhengzhou, Henan Province, People’s Republic of China. Tel/Fax: +86-0371-6558-0014. E-mail:
yuanqian001@126.com page: 53
|
MATERIALS AND METHODS
different reports regarding the T10003C mutation, we
performed a systematic review for this mutation using the
Google scholar, PubMed Central and Human MITOMAP
database. The literature search was carried out using these
combined keywords: “mitochondrial T10003C mutation”
or “mitochondrial T10003C variant.” We excluded studies
if the crucial data were not reported in original paper.
Evolutionary Conservation Analysis. To understand
the potential pathogenic role of the T10003C mutation, we
analyzed the CI of this mutation. Briefly, 10 vertebrate mttRNAGly
gene sequences were selected for this analysis. The
conservation index (CI) was then calculated by comparing
the human nucleotide variants with nine other vertebrates
[10]. We regarded the CI as the percentage of species from
the list of 10 different primates that have the wild-type at
the corresponding position. The CI >75.0% was proposed
to have a functional potential.
Haplogroup Analysis. We used the Phylotree (www.
phylotree.org) to determine the haplogroup status of the
T10003C mutation [11].
Prediction of the Secondary Structure of tRNAGly
With and Without the T10003C Mutation. We used the
RNA Fold Webserver program (http://rna.tbi.univie.ac.at/
cgi-bin/RNAfold.cgi) to predict the secondary structures
of the wild-type version of mt-tRNAGly and the mutant
carrying the T10003C mutation [12].
Mutational Analysis of the T10003C Mutation.
Five hundred unrelated DM patients including 250 male
and 250 females were recruited from the Department of
Endocrinology and Metabolism, People’s Hospital of
Zhengzhou University, Zhengzhou, Zhengzhou, Henan
Province, People’s Republic of China. The age ranged
from 50 to 80 years with the median at 61. In addition, 300
healthy, age- and gender-matched controls, obtained from
the same area were also enrolled in this study. This study
was approved by the Ethics Committee of the People’s
Hospital of Zhengzhou University.
The clinical diagnosis of DM was according to the
American Diabetes Association criteria: the level of fasting
plasma glucose of ≥7.0 mmol/dL, or the level of the oral
glucose tolerance ≥1.11 mmol/dL, or Hb A1c concentration
≥6.5% [13]. Determination of the T10003C mutation
was performed by polymerase chain reaction (PCR) amplification
and sequencing analysis of the targeted region
spanning the mt-tRNAGly gene. The following primers were
used: forward 5’-TCT CCA TCT ATT GAT GAG GGT
CT-3’; reverse 5’-AAT TAG GCT GTG GGT GGT TG-
3’; after PCR amplification, the fragment was purified
and subsequently analyzed by direct sequencing in an
ABI PRISM® 3700 automatic DNA sequencer using the
BigDye Terminator Cycle sequencing reaction kit (Applied
Biosystems Inc., Foster City, CA, USA). The data was
then compared with the reversed consensus Cambridge
sequence (GenBank Accession No. NC_12920) [14].
Statistical Analyses. We used the Statistical Package
for the Social Sciences (SPSS), version 17.0 software to
analyze the statistical significance (SPSS Inc., Chicago,
IL, USA). Fisher’s exact test was performed to evaluate
the differences in categorical variables, and a value of p
<0.05 was regarded as statistically significant.
|
|
|
|



 |
Number 27 VOL. 27 (2), 2024 |
Number 27 VOL. 27 (1), 2024 |
Number 26 Number 26 VOL. 26(2), 2023 All in one |
Number 26 VOL. 26(2), 2023 |
Number 26 VOL. 26, 2023 Supplement |
Number 26 VOL. 26(1), 2023 |
Number 25 VOL. 25(2), 2022 |
Number 25 VOL. 25 (1), 2022 |
Number 24 VOL. 24(2), 2021 |
Number 24 VOL. 24(1), 2021 |
Number 23 VOL. 23(2), 2020 |
Number 22 VOL. 22(2), 2019 |
Number 22 VOL. 22(1), 2019 |
Number 22 VOL. 22, 2019 Supplement |
Number 21 VOL. 21(2), 2018 |
Number 21 VOL. 21 (1), 2018 |
Number 21 VOL. 21, 2018 Supplement |
Number 20 VOL. 20 (2), 2017 |
Number 20 VOL. 20 (1), 2017 |
Number 19 VOL. 19 (2), 2016 |
Number 19 VOL. 19 (1), 2016 |
Number 18 VOL. 18 (2), 2015 |
Number 18 VOL. 18 (1), 2015 |
Number 17 VOL. 17 (2), 2014 |
Number 17 VOL. 17 (1), 2014 |
Number 16 VOL. 16 (2), 2013 |
Number 16 VOL. 16 (1), 2013 |
Number 15 VOL. 15 (2), 2012 |
Number 15 VOL. 15, 2012 Supplement |
Number 15 Vol. 15 (1), 2012 |
Number 14 14 - Vol. 14 (2), 2011 |
Number 14 The 9th Balkan Congress of Medical Genetics |
Number 14 14 - Vol. 14 (1), 2011 |
Number 13 Vol. 13 (2), 2010 |
Number 13 Vol.13 (1), 2010 |
Number 12 Vol.12 (2), 2009 |
Number 12 Vol.12 (1), 2009 |
Number 11 Vol.11 (2),2008 |
Number 11 Vol.11 (1),2008 |
Number 10 Vol.10 (2), 2007 |
Number 10 10 (1),2007 |
Number 9 1&2, 2006 |
Number 9 3&4, 2006 |
Number 8 1&2, 2005 |
Number 8 3&4, 2004 |
Number 7 1&2, 2004 |
Number 6 3&4, 2003 |
Number 6 1&2, 2003 |
Number 5 3&4, 2002 |
Number 5 1&2, 2002 |
Number 4 Vol.3 (4), 2000 |
Number 4 Vol.2 (4), 1999 |
Number 4 Vol.1 (4), 1998 |
Number 4 3&4, 2001 |
Number 4 1&2, 2001 |
Number 3 Vol.3 (3), 2000 |
Number 3 Vol.2 (3), 1999 |
Number 3 Vol.1 (3), 1998 |
Number 2 Vol.3(2), 2000 |
Number 2 Vol.1 (2), 1998 |
Number 2 Vol.2 (2), 1999 |
Number 1 Vol.3 (1), 2000 |
Number 1 Vol.2 (1), 1999 |
Number 1 Vol.1 (1), 1998 |
|
|